Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCGR3B | O75015 | 1/20 | 1.00 |
| ▸ | FCGR1A | P12314 | 1/20 | 1.00 |
| ▸ | FCGR2A | P12318 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | KCNH3 | Q9ULD8 | 7/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13421296 | 0.98 | FCGR3B (0.96) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13917185 | 0.94 | FCGR3B (0.89) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13921798 | 0.92 | FCGR3B (0.84) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13420987 | 0.90 | FCGR3B (0.82) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13420936 | 0.90 | FCGR3B (0.82) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13421092 | 0.90 | FCGR3B (0.81) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13421360 | 0.90 | FCGR3B (0.81) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13917179 | 0.90 | FCGR3B (0.81) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13917186 | 0.89 | FCGR3B (0.80) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13917183 | 0.89 | FCGR3B (0.80) | FCGR3BFCGR1AFCGR2ARECQLMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167576-A1 | USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-06-06 | — | — | US | claimed |
| WO-2018048941-A2 | USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-15 | — | — | WO | claimed |
| US-20190167576-A1 | USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20190167576-A1 | USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20090075867-A1 | Triazine compounds and compositions thereof for the treatment of cancers | PROMETIC BIOSCIENCE INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20090075867-A1 | Triazine compounds and compositions thereof for the treatment of cancers | PROMETIC BIOSCIENCE INC. (CA) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167576-A1 | USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE | FCGR2A, FCGR3B, FCGR1A | FCGR3B 2/4885FCGR1A 3/4885FCGR2A 1/4885 |
| US-20090075867-A1 | Triazine compounds and compositions thereof for the treatment of cancers | MCTS1, TYR, BRAF | FCGR3B 4723/4885FCGR1A 4810/4885FCGR2A 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.